Biotechnology company developing treatments for Epstein-Barr virus (EBV)-driven diseases
Biotechnology company developing treatments for Epstein-Barr virus (EBV)-driven diseases. It uses precision engineering of immune-cell metabolism to alter specific cellular states and is advancing an IDO-1 inhibitor toward clinical trials for prevention of EBV-related pathologies, including those associated with organ transplantation.